GSK plc 对 FULC 的持仓历史
FULCRUM THERAPEUTICS INC · 医疗保健
GSK plc 在 Q3 2026 的 13F 申报中披露持有 FULC(FULCRUM THERAPEUTICS INC)1,785,714 股,市值约 US$6.6M,约占其申报组合的 1.33%,在其申报持仓中市值排名第 10 位。 GSK plc 最近 4 个申报季度中有 4 个季度披露了 FULC 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-06 · 来源: SEC EDGAR Form 13F-HR
GSK plc 对 FULC 的持仓演变
GSK plc 于 Q4 2025 首次披露 FULC 持仓:1,785,714 股(约 US$20.2M)。 在 4 次申报中,GSK plc 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 1,785,714 股、市值约 US$6.6M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.79M | $20.20M | 新进 |
| Q1 2026 | 1.79M | $13.70M | 持有 |
| Q2 2026 | 1.79M | $6.54M | 持有 |
| Q3 2026 | 1.79M | $6.61M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 FULC 与 13F 数据
FULC(FULCRUM THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 30 只申报持有 FULC,申报仓位最大的包括:EcoR1 Capital, LLC (US$24.0M), TANG CAPITAL MANAGEMENT LLC (US$23.9M), Nantahala Capital Management, LLC (US$20.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 FULC 的基金
- EcoR1 Capital, LLC 6.55M 股 · $23.97M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 6.52M 股 · $23.87M · Q2 2026
- Nantahala Capital Management, LLC 5.48M 股 · $20.04M · Q2 2026
常见问题
How long has GSK plc held FULC?
GSK plc has disclosed FULC holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is GSK plc's current position in FULC?
As of Q3 2026, GSK plc holds 1.79M shares of FULC (FULCRUM THERAPEUTICS INC), valued at $6.61M, representing 1.33% of its reported portfolio and ranking #10.
Has GSK plc been buying or selling FULC?
In the latest 13F filing (Q3 2026), GSK plc held unchanged its position in FULC.
Which other funds hold FULC?
Other major institutional holders of FULC include EcoR1 Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Nantahala Capital Management, LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.